Steering Committee

Grand MMTI –  Steering Committee


J.WolfJeffrey Wolf, MD
Clinical Professor of Medicine, Division of Hematology/Oncology
Director, Myeloma Program and Grand MMTI

Dr. Jeffrey L. Wolf is an expert in cancer of the bone marrow and blood as well as an expert in bone marrow transplantation to treat these cancers. His primary area of clinical expertise and research is myeloma, the second most common cancer of the blood. He is the director of the Multiple Myeloma Program at the UCSF Helen Diller Family Comprehensive Cancer Center.

Dr. Wolf earned his medical degree at the University of Illinois in Chicago and completed a residency in medicine at the University of California in San Diego. He completed a hematology and oncology fellowship at UCSF and a bone marrow transplantation rotation at the Fred Hutchinson Cancer Center in Seattle. He helped establish the bone marrow transplant program at the City of Hope National Medical Center in Duarte, Calif. in 1979 and the first community-hospital-based bone marrow transplant unit at Alta Bates Medical Center in Berkeley in 1984. Dr. Wolf, who joined the UCSF Division of Hematology and Oncology in February 2007, is a clinical professor of medicine at UCSF.

T.MartinThomas Martin, III, MD
Clinical Professor of Medicine, Division of Hematology/Oncology
Director, Clinical Research, Hematologic Malignancies Program
Associate Director, Grand MMTI

A leading expert in hematology-oncology, Dr. Thomas Martin is the associate director of the Myeloma Institute and director of the Unrelated Donor Transplantation Program for adults at UCSF Medical Center. He is also clinical research director of hematologic malignancies, or blood cancers, at the UCSF Helen Diller Family Comprehensive Cancer Center. His research interests include developing treatments for myeloma and leukemia as well as expanding the use of bone marrow transplants. He has a special interest in umbilical cord blood transplants and is involved in efforts to improve the outcomes following unrelated donor transplants.

Dr. Martin earned an undergraduate degree at Cornell University and a medical degree at the University of Connecticut, School of Medicine in Farmington, Conn. After a medical residency at Harbor-UCLA Medical Center in Torrance, Calif., Dr. Martin completed fellowships in hematology-oncology at UCSF, where he was promoted to an adjunct professor of medicine, division of hematology and oncology. In 1999, he joined MD Anderson Cancer Center as an assistant professor of medicine and in 2001 rejoined the faculty at UCSF.

M.ShumanMarc Shuman, MD
Professor, Departments of Medicine and Urology
Dr. Shuman is Professor of Medicine and Urology and former leader of the Prostate Cancer Program in the Comprehensive Cancer Center at UCSF. In addition to being an oncologist-hematologist, he spends a significant portion of his time as head of the UC Berkeley – UCSF Masters in Translational Medicine Anti-Medical School course. His research is focused on understanding the genetic and biochemical mechanisms of tumor progression in cancer. Previously at UCSF, Dr. Shuman was chief of the Hematology and Oncology Division, and held positions in the Comprehensive Cancer Center, including Associate Director for Research and Education, Associate Director for Program Development, and a member of the Cancer Center Executive Committee since its inception. He served as Director of the Molecular Medicine Program in the School of Medicine for several years. He obtained his MD from Thomas Jefferson Medical College and has practiced at UCSF since 1976.

F.McCormickFrank McCormick, PhD, FRS
Director, UCSF Helen Diller Family Comprehensive Cancer Center
Associate Dean, UCSF School of Medicine
David A. Wood Distinguished Professorship of Tumor Biology and Cancer Research

Dr. Frank McCormick is the Director of the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center and Associate Dean of the UCSF School of Medicine. A native of Cambridge, England, Dr. McCormick received his B.Sc. in biochemistry from the University of Birmingham (1972) and Ph.D. in biochemistry from the University of Cambridge (1975). Postdoctoral fellowships were held in the United States at SUNY at Stony Brook and in London at the Imperial Cancer Research Fund. He has been a Fellow of the Royal Society since 1996 and is currently the President of the American Association for Cancer Research. Prior to joining the UCSF faculty, Dr. McCormick pursued cancer-related work with several Bay Area biotechnology firms, including Cetus Corporation (Director of Molecular Biology, 1981-90; Vice President of Research, 1990-91) and Chiron Corporation (Vice President of Research, 1991-92). In 1992 he founded Onyx Pharmaceuticals and served as its Chief Scientific Officer until 1996. Dr. McCormick’s current research interests center on the fundamental differences between normal cells and cancer cells that can allow the development of novel therapeutic strategies. In addition to his positions as Director and Associate Dean, he holds the E. Dixon Heise Distinguished Professorship in Oncology and the David A. Wood Distinguished Professorship of Tumor Biology and Cancer Research in UCSF’s Department of Microbiology and Immunology. Dr. McCormick is the author of more than 270 scientific publications.

Joan B. Levy, PhD
Director of Translational Research, Multiple Myeloma Research Foundation
Dr. Joan Levy is the Director of Translational Research at the MMRF, where she is responsible for the planning and implementation of its scientific research portfolio. In addition she works closely with the Multiple Myeloma Research Consortium in the areas of genomic studies, tissue banking and preclinical validation of novel compounds and combinations in multiple myeloma assays and models. Dr. Levy has more than 20 years of experience in oncology and osteoporosis research in both pharmaceutical and academic settings.

Before joining the MMRF, Dr. Levy was Technical Director at The Binding Site, supporting use of Freelite, a diagnostic assay for multiple myeloma. In addition, she worked at Bayer Pharmaceutical Corporation in West Haven, CT for nine years. In that capacity, she was engaged in target identification, compound validation and project leadership in the fields of cancer and osteoporosis research. She has contributed to the delivery of novel drugs candidates for clinical studies in each of these indications.

Joan earned her PhD at the University of Vermont and then completed two postdoctoral fellowships at The Rockefeller University and later at the State University of New York at Stony Brook. Her two academic appointments were at the New York University Medical Center and Yale University, studying various aspects of cell signaling pathways involved in the pathogenesis of cancer and development of osteoporosis.

Stephanie Robertson, PhD
Director, Strategic Development, Office of Innovation, Technologies & Alliances
Stephanie Robertson, PhD, is currently the Director of Strategic Development in the Office of Innovation, Technologies & Alliances (ITA) at the University of California, San Francisco. ITA was established in 2011 under the Office of Research with the goal of providing a single interface for external partners of UCSF. Within ITA, Dr. Robertson’s group provides a constant interface throughout the lifecycle of large partnership relationships, beginning at the start of alliance development, throughout the collaboration and back to the partner for strategic evaluation of expansion, extension and additional alliances. Dr. Robertson joined UCSF in 2009 as Program Director for the Sandler Center for Drug Discovery, a consortium of researchers focused on advancing therapeutics for neglected tropical diseases, and continues to work in this role along with her role in ITA. In addition, from 2010-2011 Dr. Robertson provided oversight for the UCSF Grand Multiple Myeloma Translational Initiative (Grand MMTI) and is currently a member of the Steering Committee for this program.

Prior to joining UCSF, Dr. Robertson worked for ten years at Exelixis, Inc. During her tenure at Exelixis the company grew from start-up to over 700 employees. Her most recent position of Associate Director of R&D held responsibilities that included project management for early phase clinical programs and alliance management for several collaborations with large pharma. In addition, she served as a scientific project leader for several drug discovery programs in cancer, cardiovascular disease and metabolism. She earned an undergraduate degree in chemistry (Honors) at the University of Michigan, Ann Arbor, and a Ph.D. in chemistry at the University of California, Berkeley.